---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-127927"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T23:07:42.791420+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adicet opens ADI-270 Phase 1 enrollment in ccRCC, doses first lupus nephritis patient with ADI-001

## Summary
- Enrollment opened for Phase 1 trial of ADI-270 in metastatic/advanced clear cell renal cell carcinoma; preliminary data expected 1H25.
- First lupus nephritis patient dosed in Phase 1 trial of ADI-001; preliminary clinical data in LN anticipated 1H25.
- ADI-001 received FDA Fast Track Designation for relapsed/refractory class III or IV lupus nephritis.
- Company expects to begin enrollment in SLE, SSc, IIM, SPS in 1Q25 and AAV in 2H25.
- ADI-270 is the first gamma delta CAR T cell therapy for solid tumors to enter clinical trials.

## SEC filing metadata
- accession: 0000950170-24-127927
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017024127927/0000950170-24-127927-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017024127927/acet-20241118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-127927
- JSON: https://secwatch.observer/filing/0000950170-24-127927.json
- Plain text: https://secwatch.observer/filing/0000950170-24-127927.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.